Tata elxsi Limited has submitted its quarterly confirmation certificate to stock exchanges, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.

Regulatory Compliance Submission

The company filed the confirmation certificate with both BSE Limited and National Stock Exchange of India Limited on March 06, 2026. This submission was made pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, which mandates quarterly reporting by listed companies.

Registrar Confirmation

MUFG Intime India Private Limited, formerly known as Link Intime India Pvt. Ltd., served as the registrar and share transfer agent for this compliance exercise. The registrar issued the confirmation certificate on April 4, 2026, under reference number CSC/ELXSI/26.

The certificate confirms that securities received from depository participants for dematerialization during the quarter were properly processed and confirmed to the depositories. MUFG Intime India verified that all security certificates received for dematerialization were appropriately handled within prescribed timelines.

Certificate Verification Process

The registrar confirmed several key compliance aspects in their certificate:

• Securities received for dematerialization were confirmed or rejected to depositories as required
• All securities comprised in the certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received were mutilated and cancelled after due verification by the depository participant
• Names of depositories have been substituted in the register of members as registered owners within prescribed timelines

Stakeholder Communication

The submission was communicated to multiple stakeholders to ensure comprehensive regulatory compliance. Copies of the certificate were sent to National Securities Depository Ltd. and Central Depository Services (India) Ltd., maintaining transparency across the depository ecosystem.

This quarterly filing represents part of Tata Elxsi's ongoing commitment to regulatory compliance and transparent corporate governance practices. The certificate was digitally signed by Company Secretary Sneha Vijayakumar on April 6, 2026, ensuring authenticity and proper authorization of the submission.

Tata Elxsi has announced the establishment of a global offshore development center (ODC) for Terumo Corporation, marking a significant milestone in the company's healthcare technology partnerships. The announcement was made through a regulatory filing under Regulation 30 of SEBI regulations.

Strategic Partnership Details

The 'Terumo–Tata Elxsi Offshore Development Center' was inaugurated to support the development of Terumo's cardiac and vascular solutions. This dedicated center will strengthen engineering and innovation capabilities while enabling continuous lifecycle support across international markets.

Technology and Innovation Focus

The center brings together multidisciplinary teams, combining Tata Elxsi's expertise in design, engineering, verification, regulatory compliance, and localisation. The collaboration incorporates AI, GenAI, and digital capabilities in software engineering to enable faster development and regional adaptation while addressing the growing demand for patient-centric medical devices with improved cost efficiency and product differentiation.

Leadership Statements

Fumihisa Hirose, Company President, Cardiac & Vascular Company Terumo Corporation, stated: "This new Offshore Development Center strengthens our ability to innovate faster and deliver high-quality medical technologies across global markets. Tata Elxsi's integrated design, engineering, and regulatory expertise will help us accelerate our global product roadmap while maintaining the highest standards of safety and compliance."

Sreevatsa Sahasranaman, Sr. Vice President & Head – Healthcare & Life Sciences, Tata Elxsi, commented: "This Offshore Development Center represents a comprehensive long-term partnership model with Terumo Corporation to bring Tata Elxsi's multi-disciplinary, cross-functional and deep domain expertise to drive innovation and cost efficiencies across Terumo's Cardiovascular portfolio."

Market Impact

This development highlights Tata Elxsi's strategic focus on building long-term partnerships with global healthcare and medical device companies. The collaboration advances the reliability and performance of cardiac and vascular technologies, supporting their global availability and helping ensure they meet industry standards and the evolving needs of healthcare providers and patients.